All In MedTech

Device Trial Radar · NCT05765175

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Apr 21, 2023

Primary completion

Oct 2028

Study completion May 2032

Sponsor

Lead sponsor
Varian, a Siemens Healthineers CompanyNot on our public-company list
Sponsor type
Industry
First posted
Mar 13, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.

Conditions

  • Tachycardia, Ventricular

Interventions

  • Varian Cardiac Radioablation (CRA)Device

    Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.

  • Catheter Ablation (CA)Procedure

    Subjects randomized to the CA arm will be treated according to a uniform CA protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-primary safety endpoint: freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs)Time frame: Treatment through 12 months post-treatment
  2. Co-primary efficacy endpoint: Freedom from death, and appropriate ICD shock, and VT storm.Time frame: Death will be counted from randomization through 12 months, and shock and storm will be counted starting after a 30-day period immediately post-randomization and continuing through 12 months post randomization

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.